A Phase 1 first-in-human study evaluating safety, pharmacokinetics and efficacy of ABBV-706 as monotherapy and in combination with budigalimab (ABBV-181), carboplatin, or cisplatin in adult subjects with advanced solid tumors
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
AbbVie Inc.
Start Date
January 11, 2024
End Date
January 10, 2027
Administered By
Duke Cancer Institute
Awarded By
AbbVie Inc.
Start Date
January 11, 2024
End Date
January 10, 2027